Navigation Links
Alseres Pharmaceuticals, Inc.'s Chairman, Peter Savas, Reviews Company's Progress in its Annual Letter to Stockholders

HOPKINTON, Mass., June 12 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) released a letter to stockholders from Peter G. Savas, Chairman and Chief Executive Officer, in conjunction with the company's annual stockholders meeting. The letter which follows, summarizes the Company's progress and describes its strategy going forward.
(Logo: )

The text follows:

Dear Stockholders:

I would like to review the major accomplishments of the past year and provide some insight into our strategy going forward. Last year I stated that we would continue with our plans to transform Alseres into a leading nerve repair company. Our 2007 results reflect our continued progress towards realizing commercial value from our new product pipeline.

-- Alseres' Cethrin(R) is the world's leading clinical stage nerve repair

product. Cethrin Phase I/IIa interim results demonstrated promising

neurological recovery in the first 37 enrolled patients. In January

2008, enrollment in the Phase I/IIa trial concluded with a total of 48

patients. Based on interim results, Alseres intends to move forward

with its Cethrin Phase IIb trial in the second half of 2008. After

discussions with regulatory authorities and expert advisors we were

able to reduce the planned size of the IIb trial from 200 patients to a

maximum of 100. This significantly reduced the time and funding

required to complete the Phase IIb trial. We plan to initiate the

Phase IIb trial at up to 80 sites in the United States, Canada, Europe

and other selected countries.

-- Cethrin works by inhibiting the action of Rho, a key enzyme that

prevents axon (nerve) regeneration. Rho potentially plays an important

role in a wide range of indications, including acute spinal cord injury,

stroke, bone regeneration, cardiomyopathy and oncology. Alseres has

ongoing, sponsored-research for approaches to activate pro-regenerative

pathways that stimulate axon regeneration and for approaches to

deactivate anti-regenerative pathways that inhibit axon regeneration.

We believe that our Rho inhibitor technology is a fertile and

potentially valuable platform for continued new product research and


-- Altropane(R), the company's lead molecular imaging product candidate,

is in Phase III clinical trials for the diagnosis of Parkinson's

Disease in patients with tremor. After a series of discussions with

the FDA and our expert advisors, we designed a two-part Phase III

program, termed POET-2. The first part of the program is presently

enrolling patients, as planned, in a 7-center clinical study to

generate an image training set. These images will be used to train the

expert readers in the study, as is customary for clinical trials of

molecular imaging agents. The second part of the program involves two

concurrent, replicate Phase III trials which are planned to be

initiated as soon as final agreement with FDA is reached. In addition,

by the end of the year, we plan to begin Phase II trials of Altropane,

in a new indication to aid in the diagnosis of Dementia with Lewy

Bodies "DLB".

-- We entered into an option agreement whereby Alseres can exercise an

option to amend certain terms of its Cethrin license with BioAxone

Therapeutic, Inc. in exchange for a $7 million fee payable on or before

October 27, 2008. If Alseres exercises this option, the pre-commercial

milestone payments in the amended license agreement will be reduced

from $25 million to $7 million and payable on or before December 31,

2009. In addition, the sales-based royalties in the amended license

agreement will be reduced from 10-12% to 4% for spinal cord injury and

1% for all other indications.

-- In March, Alseres entered into an agreement that provides for the

Company to borrow $5 million from Robert L. Gipson, an existing lender.

The agreement further provides that the Company may borrow up to an

additional $5 million from any existing lender under the agreement on

the same terms and conditions.

We are pursuing a growing number of confidential partnering discussions with leading companies regarding our molecular imaging, our nerve repair and our regenerative therapy programs and assets. Our recent agreement to improve the terms of the Cethrin license may represent a major step forward for Alseres in realizing the full value of our Cethrin spinal cord program and our Rho inhibitor technology platform and, most importantly, may open up key partnering opportunities.

Our primary objective is to bring our promising lead products to market efficiently. Our ability to accomplish our commercialization objective is enabled by an organization that has developed credible relationships with regulatory authorities, world experts and potential partners. In that regard, I am pleased to acknowledge that MIT Professor Robert Langer, a member of our Board and Chairman of our Science and Technology Committee, has been awarded the 2008 Millennium Technology Prize for intelligent drug delivery. The Prize, which is the world's largest for technology innovation, is given by the Technology Academy Finland. Professor Robert Langer's innovations have had a significant impact on fighting cancer, heart disease, and numerous other diseases. Known as the father of controlled drug delivery and tissue engineering, Professor Langer has been cited as "one of history's most prolific inventors in medicine". Professor Langer's research laboratory at MIT is the largest biomedical engineering laboratory in the world.

In the months ahead, we will make additional announcements regarding the progress of our product, technology and business development programs. My fellow directors, officers, advisors and employees join me in thanking you for your interest and encouragement. We remain committed to creating sustainable, long term value for all of our stockholders.

Peter G. Savas

Chairman & Chief Executive Officer

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Alseres is a trademark and Cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc.


Sharon Correia -- 508-497-2360 ext. 224

Alseres Pharmaceuticals, Inc.

Adam Friedman -- 212-981-2529 ext. 18

Adam Friedman Associates

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
4. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
5. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
6. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
7. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
8. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
(Date:9/20/2017)... ... September 20, 2017 , ... “The Financial Favor of God; Second Edition”: a ... Second Edition” is the creation of published author, Brooks Rathell. , “We typically hear ... to you about the financial favor of God. Not only does it exist, but ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were selected to receive ... Ross A. Clevens, MD, FACS . The founder and medical director of Clevens ... who trained at Yale, Harvard and the University of Michigan. He has served patients ...
(Date:9/19/2017)... ... September 19, 2017 , ... Peter ... the President’s Malaria Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project , ... , The Innovation to Action Award, a USAID Catalyst Award, recognizes USAID ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ... Canyon Ranch to its recently formed Corporate Roundtable, a group of individuals ... and a sustainable world. , Canyon Ranch is a unique collection of lifestyle-based ...
(Date:9/19/2017)... ... September 19, 2017 , ... Leonard I. Linkow, DDS, DMSC, sets a new ... Xlibris on July of 2014). This book details the recent advances and techniques in ... benefit people who have lost all of their natural teeth . , In ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)...  Getinge, a leading global provider of innovative ... program -- "Color for the Kids!" -- to ... by The Children,s Heart Foundation. Pediatric patients and ... encouraged to download a coloring picture at ... the gallery on the website. For each artwork ...
(Date:9/1/2017)... , Sept. 1, 2017  Bayer will present the ... European Society for Medical Oncology (ESMO) 2017 Congress, September 8-12 ... will include new preclinical and clinical data on Bayer,s marketed ... earlier pipeline projects. ... best minds in cancer research at ESMO," said Carsten ...
(Date:8/28/2017)... ®, a division of LightScalpel ®, LLC, is announcing its new ... years of American veterinary laser surgery innovation, Aesculight® is revolutionizing veterinary laser ... ... his new VetScalpel laser. Dr. Duclos practices veterinary dermatology at the Animal ... ...
Breaking Medicine Technology: